What is KARD's 12-month stock price target?

Kardigan Inc. (KARD) carries a 12-month consensus base price target of $13.44 (-5.4% from $14.21), with a bull-case target of $28.35 and a bear-case floor of $10.48.

Stock Ratings / Health Care / KARD / forecast

DMRA (35) NKTR (20) OMER (41) AAPG (45) ⌘ Pro Terminal →

Kardigan Inc. (KARD) 12-Month Stock Forecast & Price Target Cone

Q: Is KARD stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates KARD D (Sell — SELL) with an RQD Confidence score of 46/100.

$14.21 +0.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.20

Kardigan Inc. (KARD) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $1.32B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KARD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KARD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Kardigan Inc. (NASDAQ: KARD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $14.21 (+0.57% 1D, market cap $1.32B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KARD ranks #328 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KARD compare to DMRA and NKTR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KARD carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DMRA (Damora Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and NKTR (Nektar Therapeutics) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B). Among the 5-stock peer group, KARD leads on earnings multiple (N/A) while DMRA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KARD?

▼

Per KARD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002123613), Kardigan Inc. generated $164.2M in revenue, $0 in net income, and $0 in free cash flow against $390.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $14.20 (-0.09%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 22.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KARD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY KARD SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 22.5% FCF Margin ($37.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$12.97+4.2% Next Q

Q2 (-2Q)

Grade D$13.51+0.7% Next Q

Q3 (-1Q)

Grade D$13.60+4.5% Next Q

Current

Grade D$14.21-6.1% Hist 90D α

Trajectory: E (38) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KARD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KARD currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.07) and Max Pain ($14.92) forces dealer call-delta covering toward $28.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KARD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KARD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your KARD Position Size: $10,000

Shares at $14.21: 703.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $10.48

$7,375

$-2,625 (-26.2%)

12M Consensus BaseTarget $13.44

$9,458

$-542 (-5.4%)

12M Bull Case BreakoutTarget $28.35

$19,951

+$9,951 (+99.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$14	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$27	69%	B
JP MorganUS Large-Cap Research	SELL	$12	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KARD)

✓Walkthrough of KARD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KARD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.41%⚡ TESTING RESISTANCE

2026-11-03O $14.31H $14.31L $14.13C $14.21VOL 452.8K

RES: $14.37SUP: $9.38SMA50: $16.07SMA200: $18.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KARD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KARD Butterfly Map → + Track KARD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KARD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KARD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KARD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KARD)

Health Care Rank #328 of 1016 ⚔️ DMRA vs KARD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KARD vs. DMRA, NKTR, OMER, AAPG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kardigan Inc. (KARD) ranks #328 by composite RQD confidence (46/100, grade D) and #321 by equity capitalization ($1.32B). Within this direct 5-issuer industry benchmark cohort, KARD leads on earnings valuation at N/A trailing P/E, while DMRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KARD currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KARD ACTIVE Kardigan Inc.	D	46/100	—	—	—	+0.57%	$1.32B	Benchmark Subject
DMRA Damora Therapeutics Inc.	D-	35/100	—	—	-35.0%	+0.51%	$1.33B	/dmra-vs-kard →
NKTR Nektar Therapeutics	E	20/100	—	96.0%	-35.0%	-4.94%	$1.33B	/nktr-vs-kard →
OMER Omeros Corporation	D-	41/100	—	—	-35.0%	-3.31%	$1.33B	/omer-vs-kard →
AAPG Ascentage Pharma Group International American Depository Shares	D	45/100	—	—	—	-6.20%	$1.35B	/aapg-vs-kard →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002123613

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kardigan Inc. (KARD) reported GAAP revenue of $164.2M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KARD closed FY2025 with $390.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$164.2M	$0	—	—	$390.9M	—

3. KARD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KARD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does KARD compare to DMRA and NKTR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for KARD?

Where is KARD trading relative to its 50-day, 200-day, and 52-week technical levels?

KARD last traded at $14.21 (+0.57% on volume of 462,309 shares), positioning the stock -11.57% below its 50-day simple moving average ($16.07) and -24.74% below its 200-day simple moving average ($18.88). Across its 52-week range of $12.23 to $27.00, KARD sits at the 13.4% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.43 to $15.99).

Direct Sub-Reports: KARD RQD Cockpit KARD 12M Forecast KARD Earnings & Move KARD Dividends & DRIP KARD Insiders & 13F KARD Whale Options KARD Profit Sankey KARD News & Why

ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

KARD — Kardigan Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:13:46Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

KARD scores 45 out of 100, earning a "D" letter grade and the verdict "Roarable Sell — Underperform / Distribution Warning." The score is built from five pillars:

Fundamental Cash Engine (10 / 20): ROIC is 0% and FCF yield is 0%. For a prospective investor, this means the source data shows no measurable return on invested capital and no free-cash-flow yield to support valuation today.
Whale 13F Flow (5 / 20): this pillar reflects institutional accumulation and options positioning and scores weakly. Investor implication: institutional signals in the source data do not provide strong support.
Insider Conviction (9 / 20): SEC Form 4 and Congressional PTR cluster flow scores weakly. Investor implication: insider and congressional flow does not currently offer a strong conviction signal.
Macro Regime Fit (8 / 20): beta is 1.0 and sector sensitivity is scored at 8 of 20. Investor implication: the stock's market sensitivity is neutral in magnitude, but the regime-fit score remains low.
Forensic Balance Sheet (13 / 20): Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar, indicating a comparatively steadier balance sheet than the cash-generation and flow pillars.

Upside drivers in the source data are limited to the balance-sheet pillar and the recent positive analyst headlines. Taken together, the score points to a stock whose current evidence base is thin on profitability and cash generation.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kardigan Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $1.3B. The specific products sold, customer base, and revenue model are —

Reported revenue, operating income, and net income are each — for FY 2025, and gross, operating, and net margins are each 0% per the market data. ROIC is 0%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5, indicating a balance sheet the source rates as moderately sound. Reported cash is $109.0M, while debt is N/A in the source data.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Positive analyst initiations from UBS (buy) and Baird (Outperform, $43 target) with a 13/20 forensic balance-sheet score. With Fundamental Cash Engine at 10/20 (ROIC —, FCF yield —) and Institutional Whale Flow at 5/20, sustained execution supports upside toward the top of the $12.23 – $27.00 52-week range.
🐻 Primary Bear Case: ROIC and FCF yield both at 0% with a 45/100 RQD score, rated Underperform / Distribution Warning. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The only sector context provided is the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification. A prospective investor should note that the absence of mapped links means ripple effects cannot be assessed from the supplied data.

Key Question #1: What are the reported P/E, forward P/E, and EPS figures, given that these metrics are —?
Key Question #2: What are the FY 2025 debt and free-cash-flow amounts, which are listed as N/A?
Key Question #3: What is the basis for the InvestingPro Fair Value 50% decline prediction, and how does it reconcile with the positive analyst initiations?

KARD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kardigan Inc. (KARD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KARD Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 21h ago

Kardigan, Inc. (KARD) stock price, news, quote and history

Yahoo Finance Singapore report covering Kardigan Inc. (KARD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

InvestingPro Fair Value predicted 50% decline in Kardigan stock By Investing.com

Investing.com report covering Kardigan Inc. (KARD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Kardigan, Inc. (NASDAQ:KARD) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

MarketBeat report covering Kardigan Inc. (KARD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

UBS initiates Kardigan stock with buy rating on cardiology pipeline

Investing.com report covering Kardigan Inc. (KARD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Baird Initiates Coverage on Kardigan With Outperform Rating, $43 Price Target

Yahoo Finance report covering Kardigan Inc. (KARD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Kardigan (KARD) Short Interest & Short Float | Updated Oct 2026

MarketBeat report covering Kardigan Inc. (KARD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Kardigan (NASDAQ:KARD) Stock Lifted to Strong-Buy by Robert W. Baird

MarketBeat report covering Kardigan Inc. (KARD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com UK • 1d ago

Baird initiates Kardigan stock with Outperform rating, $43 target By Investing.com

Investing.com UK report covering Kardigan Inc. (KARD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KARD Bull vs. Bear Conversation Board — What's Your Call at $14.21?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KARD 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $16.96 (+20.0%)

📌 Pinned Debate

Positive analyst initiations from UBS (buy) and Baird (Outperform, $43 target) with a 13/20 forensic balance-sheet score.

Long KARD at $14.13 targeting $16.96. Positive analyst initiations from UBS (buy) and Baird (Outperform, $43 target) with a 13/20 forensic balance-sheet score.. Institutional whale score is 5/20 and the risk/reward vs. the $12.23 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

Both sides have a point here — KARD's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $11.45 (-19.0%)

Spot @ $14.13

ROIC and FCF yield both at 0% with a 45/100 RQD score, rated Underperform / Distribution Warning.

I respect the product at Kardigan Inc., but the stock at $14.13 is a different story. ROIC and FCF yield both at 0% with a 45/100 RQD score, rated Underperform / Distribution Warning.. FCF yield is 0.0% and RQD sits at 46/100 (D) — why pay up here when you can wait for next quarter's numbers?